Glasgow-based MindMate, a free mobile health app that is already being used by over one million people who suffer from Alzheimer’s disease, dementia, brain injury and other forms of cognitive decline, has partnered with Actinogen Medical, an Australia-headquartered biotechnology company who are developing novel treatments for Alzheimer’s and other age-related neurodegenerative disorders.
The partnership will see Actinogen use MindMate’s cognitive health software to recruit patients for the Australian Securities Exchange-listed company’s pioneering XanADu trial, currently in Phase-II to prove the effectiveness of its Xanamem drug in patients with Alzheimer’s. Xanamem aims to inhibit the excess production of the stress hormone cortisol in the brain, and was developed in response to evidence that high cortisol levels have a strong association with Alzheimer’s.
Earlier this year MindMate raised approximately $2 million from a series of international investors to accelerate new therapies in the clinical research space.
Susanne Mitschke, MindMate’s CEO and co-founder, said: “This partnership is a fantastic opportunity to collaborate with one of the leading research organizations in Scotland and shows that Scotland is continuing to drive innovation also through world-leading biotech developments.”
In the UK alone, more than 850,000 people live with Alzheimer’s and this number is projected to increase to over 1 million over the next 6 years.
In Q1 of 2018, MindMate raised approximately $2 million from a series of international investors to accelerate new therapies in the clinical research space.
MindMate is a free cognitive health &a lifestyle app used by over 1 million people worldwide. Available on iOS, MindMate helps baby boomers to manage their cognitive health through daily games and challenges, tailored physical exercises, nutrition advice plus tracking mood & sleep. Users also have access to discuss relevant clinical studies with researchers in their area.
MindMate was co-founded by CEO Susanne Mitschke, COO Patrick Renner and CTO Rogelio Arellano in 2015. In 2016, the company was selected as the first ever Scottish startup to join Techstars NYC accelerator programme. Earlier this year, Susanne, Patrick and Rogelio were named as Forbes 30 Under 30 Social Entrepreneurs by Forbes.
Headquartered in Glasgow, Scotland and with a second office in Los Angeles, MindMate has considerable scope to make an impact in the world’s two largest healthcare markets, Europe and the US.
Subscribe to our newsletter to get stories like this delivered directly to your inbox